Trajectories of disease-modifying therapies and associated sickness absence and disability pension among people with multiple sclerosis

被引：0

作者：

Teni, F. S. ^{[1
]}

Machado, A. ^{[1
]}

Murley, C. ^{[1
]}

He, A. ^{[2
]}

Fink, K. ^{[2
]}

Gyllensten, H. ^{[3
]}

Glaser, A. ^{[2
]}

Alexanderson, K. ^{[1
]}

Hillert, J. ^{[2
]}

Friberg, E. ^{[1
]}

机构：

[1] Karolinska Inst, Div Insurance Med, Dept Clin Neurosci, Stockholm, Sweden

[2] Karolinska Inst, Div Neurol, Dept Clin Neurosci, Stockholm, Sweden

[3] Univ Gothenburg, Inst Hlth & Care Sci, Sahlgrenska Acad, Gothenburg, Sweden

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

基金：

瑞典研究理事会;

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P770

引用

页码：672 / 673

页数：2

共 50 条

[31] Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA
Hartung, Daniel M.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2021, 21 (07)
[32] Comparing the efficacy of disease-modifying therapies in multiple sclerosis
Mitsikostas, Dimos D.
Goodin, Douglas S.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 109 - 116
[33] The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis
Kretzschmar, Benedikt
Pellkofer, Hannah
Weber, Martin S.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (04)
[34] Assessing the risk of multiple sclerosis disease-modifying therapies
Ayrignac, Xavier
Bilodeau, Philippe-Antoine
Prat, Alexandre
Girard, Marc
Labauge, Pierre
Le Lorier, Jacques
Larochelle, Catherine
Duquette, Pierre
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (07) : 695 - 706
[35] Adherence to disease-modifying therapies in patients with multiple sclerosis
Koltuniuk, Aleksandra
Rosinczuk, Joanna
PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1557 - 1565
[36] Impact of Disease-Modifying Therapies on Fatigue in Multiple Sclerosis
Voelter, H. U.
Hildebrandt, H.
Kastrup, A.
AKTUELLE NEUROLOGIE, 2016, 43 (08) : 511 - 518
[37] The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis
Benedikt Kretzschmar
Hannah Pellkofer
Martin S. Weber
Current Neurology and Neuroscience Reports, 2016, 16
[38] Current and future disease-modifying therapies in multiple sclerosis
Lim, S. Y.
Constantinescu, C. S.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 637 - 650
[39] Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, Alexander
Loebermann, Micha
Reisinger, Emil C.
Hartung, Hans-Peter
Zettl, Uwe K.
NATURE REVIEWS NEUROLOGY, 2016, 12 (04) : 217 - 233
[40] The Disability Outcomes of Disease-Modifying Drugs in Multiple Sclerosis
Hader, Walter
NEUROLOGY, 2012, 78

← 1 2 3 4 5 →